07:00 , Oct 8, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 2 group F member 2 (NR2F2; COUP-TFII)

Cardiovascular disease INDICATION: Cardiomyopathy In vitro and mouse studies suggest inhibiting NR2F2 in cardiomyocytes could help treat dilated cardiomyopathy. Levels of NR2F2 were higher in myocardial tissue from dilated cardiomyopathy patients than healthy controls. In mice, cardiomyocyte-specific...
08:00 , Jan 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Nuclear receptor subfamily 2, group F, member 2 (NR2F2; COUP-TFII) Studies in mice suggest that inhibiting...